DNLI
Income statement / Annual
Last year (2024), Denali Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Denali Therapeutics Inc.'s net income was -$422.77 M.
See Denali Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$330.53 M |
$108.46 M |
$48.66 M |
$335.66 M |
$26.68 M |
$129.16 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$16.73 M
|
$7.03 M
|
$5.61 M
|
$212.62 M
|
$193.38 M
|
$7.42 M
|
$3.08 M
|
$1.47 M
|
$121,000.00
|
| Gross Profit |
$0.00
|
$313.81 M
|
$101.43 M
|
$43.05 M
|
$123.04 M
|
-$166.70 M
|
$121.75 M
|
-$3.08 M
|
-$1.47 M
|
-$121,000.00
|
| Gross Profit Ratio |
0
|
0.95
|
0.94
|
0.89
|
0.37
|
-6.25
|
0.94
|
0
|
0
|
0
|
| Research and Development Expenses |
$396.44 M
|
$423.88 M
|
$358.73 M
|
$265.35 M
|
$212.62 M
|
$193.38 M
|
$143.18 M
|
$74.46 M
|
$75.70 M
|
$11.57 M
|
| General & Administrative Expenses |
$105.44 M
|
$103.35 M
|
$90.48 M
|
$79.06 M
|
$60.33 M
|
$46.48 M
|
$32.35 M
|
$15.68 M
|
$11.73 M
|
$5.11 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$105.44 M
|
$103.35 M
|
$90.48 M
|
$79.06 M
|
$60.33 M
|
$46.48 M
|
$32.35 M
|
$15.68 M
|
$11.73 M
|
$5.11 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$501.88 M
|
$527.23 M
|
$449.21 M
|
$344.41 M
|
$272.94 M
|
$239.86 M
|
$175.53 M
|
$90.14 M
|
$87.43 M
|
$16.68 M
|
| Cost And Expenses |
$0.00
|
$527.23 M
|
$449.21 M
|
$344.41 M
|
$272.94 M
|
$239.86 M
|
$175.53 M
|
$90.14 M
|
$87.43 M
|
$16.68 M
|
| Interest Income |
$0.00
|
$51.51 M
|
$14.77 M
|
$4.60 M
|
$9.14 M
|
$15.22 M
|
$10.13 M
|
$1.96 M
|
$781,000.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$14.77 M
|
$0.00
|
$0.00
|
$15.22 M
|
$0.00
|
$1.96 M
|
$0.00
|
$109,000.00
|
| Depreciation & Amortization |
$0.00
|
$16.73 M
|
$7.03 M
|
$5.61 M
|
$6.17 M
|
$7.99 M
|
$7.42 M
|
$3.08 M
|
$1.47 M
|
$121,000.00
|
| EBITDA |
-$487.34 M |
-$179.97 M |
-$330.36 M |
-$287.16 M |
$62.72 M |
-$205.19 M |
-$38.96 M |
-$87.06 M |
-$85.96 M |
-$15.06 M |
| EBITDA Ratio |
0
|
-0.54
|
-3.05
|
-6.08
|
0.19
|
-7.99
|
-0.36
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-0.6
|
-3.14
|
-6.08
|
0.19
|
-7.99
|
-0.36
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$64.64 M
|
$51.51 M
|
$14.77 M
|
$4.60 M
|
$9.24 M
|
$15.22 M
|
$10.13 M
|
$1.96 M
|
$781,000.00
|
-$109,000.00
|
| Income Before Tax |
-$422.71 M
|
-$145.19 M
|
-$325.97 M
|
-$291.16 M
|
$71.96 M
|
-$197.97 M
|
-$36.24 M
|
-$88.19 M
|
-$86.65 M
|
-$16.79 M
|
| Income Before Tax Ratio |
0
|
-0.44
|
-3.01
|
-5.98
|
0.21
|
-7.42
|
-0.28
|
0
|
0
|
0
|
| Income Tax Expense |
-$68,000.00
|
$30,000.00
|
$21,000.00
|
-$575,000.00
|
$823,000.00
|
-$351,000.00
|
$10.13 M
|
-$3.08 M
|
$0.00
|
$0.00
|
| Net Income |
-$422.77 M
|
-$145.22 M
|
-$325.99 M
|
-$290.58 M
|
$71.14 M
|
-$197.61 M
|
-$36.24 M
|
-$88.19 M
|
-$86.65 M
|
-$16.79 M
|
| Net Income Ratio |
0
|
-0.44
|
-3.01
|
-5.97
|
0.21
|
-7.41
|
-0.28
|
0
|
0
|
0
|
| EPS |
-2.57 |
-1.06 |
-2.6 |
-2.39 |
0.65 |
-2.07 |
-0.39 |
-5.89 |
-13.49 |
-5.58 |
| EPS Diluted |
-2.57 |
-1.06 |
-2.6 |
-2.39 |
0.63 |
-2.07 |
-0.39 |
-5.89 |
-13.49 |
-5.58 |
| Weighted Average Shares Out |
$164.47 M
|
$137.37 M
|
$125.53 M
|
$121.52 M
|
$108.97 M
|
$95.61 M
|
$92.62 M
|
$14.96 M
|
$6.42 M
|
$3.01 M
|
| Weighted Average Shares Out Diluted |
$164.47 M
|
$137.37 M
|
$125.53 M
|
$121.52 M
|
$112.70 M
|
$95.61 M
|
$92.62 M
|
$14.96 M
|
$6.42 M
|
$3.01 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
